Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real-world cohort study of PD-1 blockade plus lenvatinib for advanced intrahepatic cholangiocarcinoma: effectiveness, safety, and biomarker analysis
Jiashuo Chao, Shanshan Wang, Hao Wang, et al.
Cancer Immunology Immunotherapy (2023) Vol. 72, Iss. 11, pp. 3717-3726
Open Access | Times Cited: 8

Showing 8 citing articles:

Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 5
The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study
Yuanze Cai, Wu Wen, Ying Xia, et al.
Current Oncology (2025) Vol. 32, Iss. 2, pp. 87-87
Open Access
Comparison analysis of ICIs and chemotherapy combined with or without lenvatinib as first-line treatment of unresectable intrahepatic cholangiocarcinoma
Miao Li, Tong Li, Rongxin Chen, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Adrenomedullin Inhibits the Efficacy of Combined Immunotherapy and Targeted Therapy in Biliary Tract Cancer by Disrupting Endothelial Cell Functions
Zhengfeng Xuan, Haoran Hu, Jian Xu, et al.
Journal of Cellular and Molecular Medicine (2025) Vol. 29, Iss. 5
Open Access
Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
Qingyu Xu, Chendong Wang, Ran You, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
Tumor budding in pre-neoadjuvant biopsy and post-neoadjuvant resection specimens is associated with poor prognosis in intrahepatic cholangiocarcinoma—a cohort study of 147 cases by modified ITBCC criteria
Gaohua Wu, Rongkui Luo, Qianhui Xu, et al.
Virchows Archiv (2024) Vol. 485, Iss. 5, pp. 913-923
Open Access | Times Cited: 2
The fibrosis-4 index is a prognostic factor for cholangiocarcinoma patients who received immunotherapy
Zhiwei Zhang, Jingzhao Zhang, Ming Cai, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies
Yidan Lou, Yijing Chen, Kaibo Guo, et al.
Biomarkers in Medicine (2024) Vol. 18, Iss. 15-16, pp. 703-715
Closed Access
Chemotherapy combined with regorafenib and immune checkpoint inhibitors as a first-line treatment for patients with advanced biliary tract cancer: a single arm phase II trial
Jianwei Liu, Shilei Bai, Yanfu Sun, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access
Page 1

Scroll to top